Bristol Myers Squibb Is Paying $350M to Expand Its Reach in Radiopharmaceuticals to Prostate Cancer

Bristol Myers Squibb is licensing global rights to a Philochem program in development for both diagnostic imaging and targeted treatment of prostate cancer. It follows the pharma giant’s entry into radiopharmaceuticals via the $4.1 billion acquisition of RayzeBio last year. The post Bristol Myers Squibb Is Paying $350M to Expand Its Reach in Radiopharmaceuticals to…

Read More

‘We Dissent’: NIH Workers Protest Trump Policies That ‘Harm the Health of Americans’

The letter is an extraordinary rebuke of the Trump administration’s actions against the NIH, which include: terminating hundreds of grants funding scientific and biomedical research; firing more than 1,000 employees this year; and moving to end billions in funds to partner institutions overseas. The post ‘We Dissent’: NIH Workers Protest Trump Policies That ‘Harm the…

Read More

How Did the AI “Claude” Get Its Name?

By MIKE MAGEE Let me be the first to introduce you to Claude Elwood Shannon. If you have never heard of him but consider yourself informed and engaged, including at the interface of AI and Medicine, don’t be embarrassed. I taught a semester of “AI and Medicine” in 2024 and only recently was introduced to “Claude.” Let’s begin…

Read More